Drug intelligence / Profile preview

GRN-1

Development stage: Preclinical
Lead developer: Grann
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

GRN-1 is an experimental mRNA therapeutic delivered via a patented solid lipid nanoparticle (SLN) system, currently under development by Grann Pharmaceuticals. It is designed to treat metabolic and liver-related conditions, including obesity, non-alcoholic fatty liver disease (NAFLD/MASLD), liver cirrhosis, and hepatic steatosis. The mechanism involves mRNA encoding proteins that modulate metabolic pathways to reduce the accumulation of adipose tissue and hepatic fat. Preclinical in vivo studies using MS-NASH mouse models have demonstrated efficacy in reducing hepatic steatosis and inflammation, indicating potential utility across various metabolic, alcoholic, or lysosomal storage-related disorders.

Other names: GRN-1-Grann-mRNA-LNP-mRNA-SLNGRN1-Grann-mRNA-LNP-mRNA-SLNGRN 1-Grann-mRNA-LNP-mRNA-SLN

Beyond the preview

Go deeper on GRN-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GRN-1.

Explore the full profile